GCTK — Glucotrack, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1506983 ·
Last close
$1.11
Market Cap
$885.9K
52W High
$125.25
52W Low
$1.07
ADV30
2,908,069
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,400,000 | -3,814,000 | 1,495,000 | 1,124,000 | 3,236,000 |
| Mar 2026 | 0 | — | -4,203,000 | -4,334,000 | 4,356,000 | 3,929,000 | 5,207,000 |
| Dec 2025 | 0 | — | -3,487,000 | -3,628,000 | 7,838,000 | 7,383,000 | 5,010,000 |
| Sep 2025 | 0 | — | -4,309,000 | -4,171,000 | 8,290,000 | 7,869,000 | 5,539,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-16,349,000
Investing CF
$-87,000
Financing CF
$11,239,000
CapEx
$-96,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-57.05
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-156,172,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-16,795,000
Pretax Income TTM
$-16,889,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -16,090,000 | -19,388,000 | 7,838,000 | 5,010,000 | 2,828,000 | -15,240,000 |
| Dec 2024 | 0 | -14,547,000 | -22,597,000 | 5,932,000 | 18,932,000 | -13,000,000 | -12,490,000 |
| Dec 2023 | 0 | -7,104,000 | -7,097,000 | 4,905,000 | 1,708,000 | 3,197,000 | -6,558,000 |
| Dec 2022 | 0 | -4,432,000 | -4,435,000 | 2,438,000 | 1,208,000 | 1,230,000 | -3,729,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$33,590,000
NetIncome TTM
$16,889,000
OpCashFlow TTM
—
Assets (Latest)
$4,356,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| YBGJ | Yubo International Biotech Ltd | $886.2K | $0.01 | — |
| LGMK | LogicMark, Inc. | $899.8K | $1.00 | — |
| PFSA | Profusa, Inc. | $902.5K | $1.49 | — |
| NUMD | Nu-Med Plus, Inc. | $848.9K | $0.01 | — |
| BJDX | Bluejay Diagnostics, Inc. | $843.9K | $0.82 | — |
News headlines (Yahoo Finance, 1h cache)
Lōkahi Therapeutics™ Expands University of Georgia Collaboration Through First International ai² Pipeline™ Project with Universität Paderborn
2026-10-01 21:15 · Yahoo
Lōkahi Therapeutics™ Announces Qare™, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14
2026-09-30 13:00 · Yahoo
Lōkahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™
2026-09-25 13:00 · Yahoo
Glucotrack, Inc. Announces Pricing of $3 Million Public Offering
2026-09-24 12:45 · Yahoo
Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating Platform
2026-09-23 20:30 · Yahoo
Glucotrack Announces $11.5 Million Financing
2026-09-11 12:00 · Yahoo
Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Collaboration with San Diego State University Fowler College of Business
2026-09-02 13:15 · Yahoo
Glucotrack, Inc. Announces Reverse Stock Split
2026-08-27 12:00 · Yahoo
Lōkahi Therapeutics™ Initiates Clinical Trial Manufacturing for LT-100
2026-08-25 12:00 · Yahoo
Glucotrack Announces $5.5 Million Financing
2026-08-05 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.